TABLE 6A - NEW DIAGNOSIS CODES
Diagnosis Code	Description	CC	MDC	MS-DRG
C81.0A	Nodular lymphocyte predominant Hodgkin lymphoma, in remission	C	17	820, 821, 822, 823, 824, 825, 840, 841, 842
C81.1A	Nodular sclerosis Hodgkin lymphoma, in remission	C	17	820, 821, 822, 823, 824, 825, 840, 841, 842
C81.2A	Mixed cellularity Hodgkin lymphoma, in remission	C	17	820, 821, 822, 823, 824, 825, 840, 841, 842
C81.3A	Lymphocyte depleted Hodgkin lymphoma, in remission	C	17	820, 821, 822, 823, 824, 825, 840, 841, 842
C81.4A	Lymphocyte-rich Hodgkin lymphoma, in remission	C	17	820, 821, 822, 823, 824, 825, 840, 841, 842
C81.7A	Other Hodgkin lymphoma, in remission	C	17	820, 821, 822, 823, 824, 825, 840, 841, 842
C81.9A	Hodgkin lymphoma, unspecified, in remission	C	17	820, 821, 822, 823, 824, 825, 840, 841, 842
C82.0A	Follicular lymphoma grade I, in remission	C	17	820, 821, 822, 823, 824, 825, 840, 841, 842
C82.1A	Follicular lymphoma grade II, in remission	C	17	820, 821, 822, 823, 824, 825, 840, 841, 842
C82.2A	Follicular lymphoma grade III, unspecified, in remission	C	17	820, 821, 822, 823, 824, 825, 840, 841, 842
C82.3A	Follicular lymphoma grade IIIa, in remission	C	17	820, 821, 822, 823, 824, 825, 840, 841, 842
C82.4A	Follicular lymphoma grade IIIb, in remission	C	17	820, 821, 822, 823, 824, 825, 840, 841, 842
C82.5A	Diffuse follicle center lymphoma, in remission	C	17	820, 821, 822, 823, 824, 825, 840, 841, 842
""			25	974(1), 975(1), 976(1)
C82.6A	Cutaneous follicle center lymphoma, in remission	C	17	820, 821, 822, 823, 824, 825, 840, 841, 842
C82.8A	Other types of follicular lymphoma, in remission	C	17	820, 821, 822, 823, 824, 825, 840, 841, 842
C82.9A	Follicular lymphoma, unspecified, in remission	C	17	820, 821, 822, 823, 824, 825, 840, 841, 842
C83.0A	Small cell B-cell lymphoma, in remission	C	17	820, 821, 822, 823, 824, 825, 840, 841, 842
""			25	974(1), 975(1), 976(1)
C83.1A	Mantle cell lymphoma, in remission	C	17	820, 821, 822, 823, 824, 825, 840, 841, 842
""			25	974(1), 975(1), 976(1)
C83.390	Primary central nervous system lymphoma	C	17	820, 821, 822, 823, 824, 825, 840, 841, 842
""			25	974(1), 975(1), 976(1)
C83.398	Diffuse large B-cell lymphoma of other extranodal and solid organ sites	C	17	820, 821, 822, 823, 824, 825, 840, 841, 842
""			25	974(1), 975(1), 976(1)
C83.3A	Diffuse large B-cell lymphoma, in remission	C	17	820, 821, 822, 823, 824, 825, 840, 841, 842
""			25	974(1), 975(1), 976(1)
C83.5A	Lymphoblastic (diffuse) lymphoma, in remission	C	17	820, 821, 822, 823, 824, 825, 840, 841, 842
C83.7A	Burkitt lymphoma, in remission	C	17	820, 821, 822, 823, 824, 825, 840, 841, 842
""			25	974(1), 975(1), 976(1)
C83.8A	Other non-follicular lymphoma, in remission	C	17	820, 821, 822, 823, 824, 825, 840, 841, 842
""			25	974(1), 975(1), 976(1)
C83.9A	Non-follicular (diffuse) lymphoma, unspecified, in remission	C	17	820, 821, 822, 823, 824, 825, 840, 841, 842
""			25	974(1), 975(1), 976(1)
C84.0A	Mycosis fungoides, in remission	C	17	820, 821, 822, 823, 824, 825, 840, 841, 842
C84.1A	Sezary disease, in remission	C	17	820, 821, 822, 823, 824, 825, 840, 841, 842
C84.4A	Peripheral T-cell lymphoma, not elsewhere classified, in remission	C	17	820, 821, 822, 823, 824, 825, 840, 841, 842
""			25	974(1), 975(1), 976(1)
C84.6A	Anaplastic large cell lymphoma, ALK-positive, in remission	C	17	820, 821, 822, 823, 824, 825, 840, 841, 842
""			25	974(1), 975(1), 976(1)
C84.7B	Anaplastic large cell lymphoma, ALK-negative, in remission	C	17	820, 821, 822, 823, 824, 825, 840, 841, 842
""			25	974(1), 975(1), 976(1)
C84.9A	Mature T/NK-cell lymphomas, unspecified, in remission	C	17	820, 821, 822, 823, 824, 825, 840, 841, 842
""			25	974(1), 975(1), 976(1)
C84.AA	Cutaneous T-cell lymphoma, unspecified, in remission	C	17	820, 821, 822, 823, 824, 825, 840, 841, 842
""			25	974(1), 975(1), 976(1)
C84.ZA	Other mature T/NK-cell lymphomas, in remission	C	17	820, 821, 822, 823, 824, 825, 840, 841, 842
""			25	974(1), 975(1), 976(1)
C85.1A	Unspecified B-cell lymphoma, in remission	C	17	820, 821, 822, 823, 824, 825, 840, 841, 842
""			25	974(1), 975(1), 976(1)
C85.2A	Mediastinal (thymic) large B-cell lymphoma, in remission	C	17	820, 821, 822, 823, 824, 825, 840, 841, 842
""			25	974(1), 975(1), 976(1)
C85.8A	Other specified types of non-Hodgkin lymphoma, in remission	C	17	820, 821, 822, 823, 824, 825, 840, 841, 842
""			25	974(1), 975(1), 976(1)
C85.9A	Non-Hodgkin lymphoma, unspecified, in remission	C	17	820, 821, 822, 823, 824, 825, 840, 841, 842
""			25	974(1), 975(1), 976(1)
C86.00	Extranodal NK/T-cell lymphoma, nasal type not having achieved remission	C	PRE	011, 012, 013
""			17	820, 821, 822, 823, 824, 825, 840, 841, 842
""			25	974(1), 975(1), 976(1)
C86.01	Extranodal NK/T-cell lymphoma, nasal type, in remission	C	PRE	011, 012, 013
""			17	820, 821, 822, 823, 824, 825, 840, 841, 842
""			25	974(1), 975(1), 976(1)
C86.10	Hepatosplenic T-cell lymphoma not having achieved remission	C	17	820, 821, 822, 823, 824, 825, 840, 841, 842
""			25	974(1), 975(1), 976(1)
C86.11	Hepatosplenic T-cell lymphoma, in remission	C	17	820, 821, 822, 823, 824, 825, 840, 841, 842
""			25	974(1), 975(1), 976(1)
C86.20	Enteropathy-type (intestinal) T-cell lymphoma not having achieved remission	C	17	820, 821, 822, 823, 824, 825, 840, 841, 842
""			25	974(1), 975(1), 976(1)
C86.21	Enteropathy-type (intestinal) T-cell lymphoma, in remission	C	17	820, 821, 822, 823, 824, 825, 840, 841, 842
""			25	974(1), 975(1), 976(1)
C86.30	Subcutaneous panniculitis-like T-cell lymphoma not having achieved remission	C	17	820, 821, 822, 823, 824, 825, 840, 841, 842
""			25	974(1), 975(1), 976(1)
C86.31	Subcutaneous panniculitis-like T-cell lymphoma, in remission	C	17	820, 821, 822, 823, 824, 825, 840, 841, 842
""			25	974(1), 975(1), 976(1)
C86.40	Blastic NK-cell lymphoma not having achieved remission	C	17	820, 821, 822, 823, 824, 825, 840, 841, 842
""			25	974(1), 975(1), 976(1)
C86.41	Blastic NK-cell lymphoma, in remission	C	17	820, 821, 822, 823, 824, 825, 840, 841, 842
""			25	974(1), 975(1), 976(1)
C86.50	Angioimmunoblastic T-cell lymphoma not having achieved remission	C	17	820, 821, 822, 823, 824, 825, 840, 841, 842
""			25	974(1), 975(1), 976(1)
C86.51	Angioimmunoblastic T-cell lymphoma, in remission	C	17	820, 821, 822, 823, 824, 825, 840, 841, 842
""			25	974(1), 975(1), 976(1)
C86.60	Primary cutaneous CD30-positive T-cell proliferations not having achieved remission	C	17	820, 821, 822, 823, 824, 825, 840, 841, 842
""			25	974(1), 975(1), 976(1)
C86.61	Primary cutaneous CD30-positive T-cell proliferations, in remission	C	17	820, 821, 822, 823, 824, 825, 840, 841, 842
""			25	974(1), 975(1), 976(1)
C88.00	Waldenstrom macroglobulinemia not having achieved remission	N	17	820, 821, 822, 823, 824, 825, 840, 841, 842
C88.01	Waldenstrom macroglobulinemia, in remission	N	17	820, 821, 822, 823, 824, 825, 840, 841, 842
C88.20	Heavy chain disease not having achieved remission	C	17	820, 821, 822, 823, 824, 825, 840, 841, 842
C88.21	Heavy chain disease, in remission	C	17	820, 821, 822, 823, 824, 825, 840, 841, 842
C88.30	Immunoproliferative small intestinal disease not having achieved remission	C	17	820, 821, 822, 823, 824, 825, 840, 841, 842
C88.31	Immunoproliferative small intestinal disease, in remission	C	17	820, 821, 822, 823, 824, 825, 840, 841, 842
C88.40	Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lymphoma] not having achieved remission	C	17	820, 821, 822, 823, 824, 825, 840, 841, 842
""			25	974(1), 975(1), 976(1)
C88.41	Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lymphoma], in remission	C	17	820, 821, 822, 823, 824, 825, 840, 841, 842
""			25	974(1), 975(1), 976(1)
C88.80	Other malignant immunoproliferative diseases not having achieved remission	C	17	820, 821, 822, 823, 824, 825, 840, 841, 842
C88.81	Other malignant immunoproliferative diseases, in remission	C	17	820, 821, 822, 823, 824, 825, 840, 841, 842
C88.90	Malignant immunoproliferative disease, unspecified not having achieved remission	C	17	820, 821, 822, 823, 824, 825, 840, 841, 842
C88.91	Malignant immunoproliferative disease, unspecified, in remission	C	17	820, 821, 822, 823, 824, 825, 840, 841, 842
D61.03	Fanconi anemia	C	16	808, 809, 810
E10.A0	Type 1 diabetes mellitus, presymptomatic, unspecified	N	PRE	008, 010, 019
""			10	637, 638, 639
E10.A1	Type 1 diabetes mellitus, presymptomatic, Stage 1	N	PRE	008, 010, 019
""			10	637, 638, 639
E10.A2	Type 1 diabetes mellitus, presymptomatic, Stage 2	N	PRE	008, 010, 019
""			10	637, 638, 639
E16.A1	Hypoglycemia level 1	N	10	643, 644, 645
E16.A2	Hypoglycemia level 2	N	10	643, 644, 645
E16.A3	Hypoglycemia level 3	N	10	643, 644, 645
E34.00	Carcinoid syndrome, unspecified	C	10	643, 644, 645
E34.01	Carcinoid heart syndrome	C	10	643, 644, 645
E34.09	Other carcinoid syndrome	C	10	643, 644, 645
E66.811	Obesity, class 1	N	10	640, 641
E66.812	Obesity, class 2	N	10	640, 641
E66.813	Obesity, class 3	N	10	640, 641
E66.89	Other obesity not elsewhere classified	N	10	640, 641
E74.820	SLC13A5 Citrate Transporter Disorder	C	10	642
E74.829	Other disorders of citrate metabolism	C	10	642
E88.82	Obesity due to disruption of MC4R pathway	N	10	642
F50.010	Anorexia nervosa, restricting type, mild	C	19	883
F50.011	Anorexia nervosa, restricting type, moderate	C	19	883
F50.012	Anorexia nervosa, restricting type, severe	C	19	883
F50.013	Anorexia nervosa, restricting type, extreme	C	19	883
F50.014	Anorexia nervosa, restricting type, in remission	C	19	883
F50.019	Anorexia nervosa, restricting type, unspecified	C	19	883
F50.020	Anorexia nervosa, binge eating/purging type, mild	C	19	883
F50.021	Anorexia nervosa, binge eating/purging type, moderate	C	19	883
F50.022	Anorexia nervosa, binge eating/purging type, severe	C	19	883
F50.023	Anorexia nervosa, binge eating/purging type, extreme	C	19	883
F50.024	Anorexia nervosa, binge eating/purging type, in remission	C	19	883
F50.029	Anorexia nervosa, binge eating/purging type, unspecified	C	19	883
F50.20	Bulimia nervosa, unspecified	C	19	887
F50.21	Bulimia nervosa, mild	C	19	887
F50.22	Bulimia nervosa, moderate	C	19	887
F50.23	Bulimia nervosa, severe	C	19	887
F50.24	Bulimia nervosa, extreme	C	19	887
F50.25	Bulimia nervosa, in remission	C	19	887
F50.810	Binge eating disorder, mild	N	19	887
F50.811	Binge eating disorder, moderate	N	19	887
F50.812	Binge eating disorder, severe	N	19	887
F50.813	Binge eating disorder, extreme	N	19	887
F50.814	Binge eating disorder, in remission	N	19	887
F50.819	Binge eating disorder, unspecified	N	19	887
F50.83	Pica in adults	N	19	887
F50.84	Rumination disorder in adults	N	19	887
G40.841	KCNQ2-related epilepsy, not intractable, with status epilepticus	C	01	023, 100, 101
G40.842	KCNQ2-related epilepsy, not intractable, without status epilepticus	C	01	023, 100, 101
G40.843	KCNQ2-related epilepsy, intractable, with status epilepticus	C	01	023, 100, 101
G40.844	KCNQ2-related epilepsy, intractable, without status epilepticus	C	01	023, 100, 101
G90.81	Serotonin syndrome	N	01	073, 074
G90.89	Other disorders of autonomic nervous system	N	01	073, 074
G93.45	Developmental and epileptic encephalopathy	C	01	070, 071, 072
""			25	974(1), 975(1), 976(1)
I26.03	Cement embolism of pulmonary artery with acute cor pulmonale	M	04	173, 175
""			15	791(2), 793(2)
I26.04	Fat embolism of pulmonary artery with acute cor pulmonale	M	04	173, 175
""			15	791(2), 793(2)
I26.95	Cement embolism of pulmonary artery without acute cor pulmonale	M	04	173, 175, 176
""			15	791(2), 793(2)
I26.96	Fat embolism of pulmonary artery without acute cor pulmonale	M	04	173, 175, 176
""			15	791(2), 793(2)
J34.8200	Internal nasal valve collapse, unspecified	N	03	154, 155, 156
""			15	795(3)
J34.8201	Internal nasal valve collapse, static	N	03	154, 155, 156
""			15	795(3)
J34.8202	Internal nasal valve collapse, dynamic	N	03	154, 155, 156
""			15	795(3)
J34.8210	External nasal valve collapse, unspecified	N	03	154, 155, 156
""			15	795(3)
J34.8211	External nasal valve collapse, static	N	03	154, 155, 156
""			15	795(3)
J34.8212	External nasal valve collapse, dynamic	N	03	154, 155, 156
""			15	795(3)
J34.829	Nasal valve collapse, unspecified	N	03	154, 155, 156
""			15	795(3)
K60.30	Anal fistula, unspecified	N	06	393, 394, 395
K60.311	Anal fistula, simple, initial	N	06	393, 394, 395
K60.312	Anal fistula, simple, persistent	N	06	393, 394, 395
K60.313	Anal fistula, simple, recurrent	N	06	393, 394, 395
K60.319	Anal fistula, simple, unspecified	N	06	393, 394, 395
K60.321	Anal fistula, complex, initial	N	06	393, 394, 395
K60.322	Anal fistula, complex, persistent	N	06	393, 394, 395
K60.323	Anal fistula, complex, recurrent	N	06	393, 394, 395
K60.329	Anal fistula, complex, unspecified	N	06	393, 394, 395
K60.40	Rectal fistula, unspecified	N	06	393, 394, 395
K60.411	Rectal fistula, simple, initial	N	06	393, 394, 395
K60.412	Rectal fistula, simple, persistent	N	06	393, 394, 395
K60.413	Rectal fistula, simple, recurrent	N	06	393, 394, 395
K60.419	Rectal fistula, simple, unspecified	N	06	393, 394, 395
K60.421	Rectal fistula, complex, initial	N	06	393, 394, 395
K60.422	Rectal fistula, complex, persistent	N	06	393, 394, 395
K60.423	Rectal fistula, complex, recurrent	N	06	393, 394, 395
K60.429	Rectal fistula, complex, unspecified	N	06	393, 394, 395
K60.50	Anorectal fistula, unspecified	N	06	393, 394, 395
K60.511	Anorectal fistula, simple, initial	N	06	393, 394, 395
K60.512	Anorectal fistula, simple, persistent	N	06	393, 394, 395
K60.513	Anorectal fistula, simple, recurrent	N	06	393, 394, 395
K60.519	Anorectal fistula, simple, unspecified	N	06	393, 394, 395
K60.521	Anorectal fistula, complex, initial	N	06	393, 394, 395
K60.522	Anorectal fistula, complex, persistent	N	06	393, 394, 395
K60.523	Anorectal fistula, complex, recurrent	N	06	393, 394, 395
K60.529	Anorectal fistula, complex, unspecified	N	06	393, 394, 395
L29.81	Cholestatic pruritus	N	09	606, 607
L29.89	Other pruritus	N	09	606, 607
L66.10	Lichen planopilaris, unspecified	N	09	606, 607
L66.11	Classic lichen planopilaris	N	09	606, 607
L66.12	Frontal fibrosing alopecia	N	09	606, 607
L66.19	Other lichen planopilaris	N	09	606, 607
L66.81	Central centrifugal cicatricial alopecia	N	09	606, 607
L66.89	Other cicatricial alopecia	N	09	606, 607
M51.360	Other intervertebral disc degeneration, lumbar region with discogenic back pain only	N	08	551, 552
M51.361	Other intervertebral disc degeneration, lumbar region with lower extremity pain only	N	08	551, 552
M51.362	Other intervertebral disc degeneration, lumbar region with discogenic back pain and lower extremity pain	N	08	551, 552
M51.369	Other intervertebral disc degeneration, lumbar region without mention of lumbar back pain or lower extremity pain	N	08	551, 552
M51.370	Other intervertebral disc degeneration, lumbosacral region with discogenic back pain only	N	08	551, 552
M51.371	Other intervertebral disc degeneration, lumbosacral region with lower extremity pain only	N	08	551, 552
M51.372	Other intervertebral disc degeneration, lumbosacral region with discogenic back pain and lower extremity pain	N	08	551, 552
M51.379	Other intervertebral disc degeneration, lumbosacral region without mention of lumbar back pain or lower extremity pain	N	08	551, 552
M62.85	Dysfunction of the multifidus muscles, lumbar region	N	08	557, 558
M65.90	Unspecified synovitis and tenosynovitis, unspecified site	N	08	557, 558
M65.911	Unspecified synovitis and tenosynovitis, right shoulder	N	08	557, 558
M65.912	Unspecified synovitis and tenosynovitis, left shoulder	N	08	557, 558
M65.919	Unspecified synovitis and tenosynovitis, unspecified shoulder	N	08	557, 558
M65.921	Unspecified synovitis and tenosynovitis, right upper arm	N	08	557, 558
M65.922	Unspecified synovitis and tenosynovitis, left upper arm	N	08	557, 558
M65.929	Unspecified synovitis and tenosynovitis, unspecified upper arm	N	08	557, 558
M65.931	Unspecified synovitis and tenosynovitis, right forearm	N	08	557, 558
M65.932	Unspecified synovitis and tenosynovitis, left forearm	N	08	557, 558
M65.939	Unspecified synovitis and tenosynovitis, unspecified forearm	N	08	557, 558
M65.941	Unspecified synovitis and tenosynovitis, right hand	N	08	557, 558
M65.942	Unspecified synovitis and tenosynovitis, left hand	N	08	557, 558
M65.949	Unspecified synovitis and tenosynovitis, unspecified hand	N	08	557, 558
M65.951	Unspecified synovitis and tenosynovitis, right thigh	N	08	557, 558
M65.952	Unspecified synovitis and tenosynovitis, left thigh	N	08	557, 558
M65.959	Unspecified synovitis and tenosynovitis, unspecified thigh	N	08	557, 558
M65.961	Unspecified synovitis and tenosynovitis, right lower leg	N	08	557, 558
M65.962	Unspecified synovitis and tenosynovitis, left lower leg	N	08	557, 558
M65.969	Unspecified synovitis and tenosynovitis, unspecified lower leg	N	08	557, 558
M65.971	Unspecified synovitis and tenosynovitis, right ankle and foot	N	08	557, 558
M65.972	Unspecified synovitis and tenosynovitis, left ankle and foot	N	08	557, 558
M65.979	Unspecified synovitis and tenosynovitis, unspecified ankle and foot	N	08	557, 558
M65.98	Unspecified synovitis and tenosynovitis, other site	N	08	557, 558
M65.99	Unspecified synovitis and tenosynovitis, multiple sites	N	08	557, 558
Q23.81	Bicuspid aortic valve	N	05	306, 307
Q23.82	Congenital mitral valve cleft leaflet	N	05	306, 307
Q23.88	Other congenital malformations of aortic and mitral valves	N	05	306, 307
Q87.86	Kleefstra syndrome	C	08	564, 565, 566
R41.85	Anosognosia	N	19	884
T45.AX1A	Poisoning by immune checkpoint inhibitors and immunostimulant drugs, accidental (unintentional), initial encounter	N	21	917, 918
T45.AX1D	Poisoning by immune checkpoint inhibitors and immunostimulant drugs, accidental (unintentional), subsequent encounter	N	23	949, 950
T45.AX1S	Poisoning by immune checkpoint inhibitors and immunostimulant drugs, accidental (unintentional), sequela	N	21	922, 923
T45.AX2A	Poisoning by immune checkpoint inhibitors and immunostimulant drugs, intentional self-harm, initial encounter	N	21	917, 918
T45.AX2D	Poisoning by immune checkpoint inhibitors and immunostimulant drugs, intentional self-harm, subsequent encounter	N	23	949, 950
T45.AX2S	Poisoning by immune checkpoint inhibitors and immunostimulant drugs, intentional self-harm, sequela	N	21	922, 923
T45.AX3A	Poisoning by immune checkpoint inhibitors and immunostimulant drugs, assault, initial encounter	N	21	917, 918
T45.AX3D	Poisoning by immune checkpoint inhibitors and immunostimulant drugs, assault, subsequent encounter	N	23	949, 950
T45.AX3S	Poisoning by immune checkpoint inhibitors and immunostimulant drugs, assault, sequela	N	21	922, 923
T45.AX4A	Poisoning by immune checkpoint inhibitors and immunostimulant drugs, undetermined, initial encounter	N	21	917, 918
T45.AX4D	Poisoning by immune checkpoint inhibitors and immunostimulant drugs, undetermined, subsequent encounter	N	23	949, 950
T45.AX4S	Poisoning by immune checkpoint inhibitors and immunostimulant drugs, undetermined, sequela	N	21	922, 923
T45.AX5A	Adverse effect of immune checkpoint inhibitors and immunostimulant drugs, initial encounter	N	15	791(2), 793(2)
""			21	917, 918
T45.AX5D	Adverse effect of immune checkpoint inhibitors and immunostimulant drugs, subsequent encounter	N	23	949, 950
T45.AX5S	Adverse effect of immune checkpoint inhibitors and immunostimulant drugs, sequela	N	21	922, 923
T45.AX6A	Underdosing of immune checkpoint inhibitors and immunostimulant drugs, initial encounter	N	23	951
T45.AX6D	Underdosing of immune checkpoint inhibitors and immunostimulant drugs, subsequent encounter	N	23	949, 950
T45.AX6S	Underdosing of immune checkpoint inhibitors and immunostimulant drugs, sequela	N	23	949, 950
T81.320A	Disruption or dehiscence of gastrointestinal tract anastomosis, repair, or closure, initial encounter	C	21	919, 920, 921
T81.320D	Disruption or dehiscence of gastrointestinal tract anastomosis, repair, or closure, subsequent encounter	N	23	949, 950
T81.320S	Disruption or dehiscence of gastrointestinal tract anastomosis, repair, or closure, sequela	N	21	922, 923
T81.321A	Disruption or dehiscence of closure of internal operation (surgical) wound of abdominal wall muscle or fascia, initial encounter	C	21	919, 920, 921
T81.321D	Disruption or dehiscence of closure of internal operation (surgical) wound of abdominal wall muscle or fascia, subsequent encounter	N	23	949, 950
T81.321S	Disruption or dehiscence of closure of internal operation (surgical) wound of abdominal wall muscle or fascia, sequela	N	21	922, 923
T81.328A	Disruption or dehiscence of closure of other specified internal operation (surgical) wound, initial encounter	C	21	919, 920, 921
T81.328D	Disruption or dehiscence of closure of other specified internal operation (surgical) wound, subsequent encounter	N	23	949, 950
T81.328S	Disruption or dehiscence of closure of other specified internal operation (surgical) wound, sequela	N	21	922, 923
T81.329A	Deep disruption or dehiscence of operation wound, unspecified, initial encounter	C	21	919, 920, 921
T81.329D	Deep disruption or dehiscence of operation wound, unspecified, subsequent encounter	N	23	949, 950
T81.329S	Deep disruption or dehiscence of operation wound, unspecified, sequela	N	21	922, 923
Z15.1	Genetic susceptibility to epilepsy and neurodevelopmental disorders	N	23	951
Z15.2	Genetic susceptibility to obesity	N	23	951
Z17.21	Progesterone receptor positive status	N	23	947, 948
Z17.22	Progesterone receptor negative status	N	23	947, 948
Z17.31	Human epidermal growth factor receptor 2 positive status	N	23	951
Z17.32	Human epidermal growth factor receptor 2 negative status	N	23	951
Z17.410	Hormone receptor positive with human epidermal growth factor receptor 2 positive status	N	23	951
Z17.411	Hormone receptor positive with human epidermal growth factor receptor 2 negative status	N	23	951
Z17.420	Hormone receptor negative with human epidermal growth factor receptor 2 positive status	N	23	951
Z17.421	Hormone receptor negative with human epidermal growth factor receptor 2 negative status	N	23	951
Z51.A	Encounter for sepsis aftercare	N	23	949, 950
Z59.71	Insufficient health insurance coverage	N	23	951
Z59.72	Insufficient welfare support	N	23	951
Z67.A1	Duffy null	N	23	951
Z67.A2	Duffy a positive	N	23	951
Z67.A3	Duffy b positive	N	23	951
Z67.A4	Duffy a and b positive	N	23	951
Z68.55	Body mass index [BMI] pediatric, 120% of the 95th percentile for age to less than 140% of the 95th percentile for age	C	10	640, 641
Z68.56	Body mass index [BMI] pediatric, greater than or equal to 140% of the 95th percentile for age	C	10	640, 641
Z83.72	Family history of familial adenomatous polyposis	N	23	951
Z86.0100	Personal history of colon polyps, unspecified	N	23	951
Z86.0101	Personal history of adenomatous and serrated colon polyps	N	23	951
Z86.0102	Personal history of hyperplastic colon polyps	N	23	951
Z86.0109	Personal history of other colon polyps	N	23	951
Z92.26	Personal history of immune checkpoint inhibitor therapy	N	23	949, 950

	Notes:
	(1)-In combination with SDX of HIV
	(2)-On newborn major problem list
	(3)-On 'Only Secondary Diagnosis' list